drugset / Trial / NCT06605690
An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, exploratory clinical study
Timeline
- Start
- 2024-10-31
- Primary completion
- 2025-08-31
- Completion
- 2026-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Dalpiciclib | Small molecule | 150 mg | Oral |
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |